Clinical Trial Update: Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for regorafenib in antiangiogenic-naive and chemotherapy-refractory advanced colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED